{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:46:27Z","timestamp":1788929187278,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.soncn.2026.152167","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:29:54Z","timestamp":1772742594000},"page":"152167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["From Serum Markers to Liquid Biopsy: Precision Monitoring in Breast, Ovarian, Pancreatic, and Prostate Cancers"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9165-9825","authenticated-orcid":false,"given":"Laurie M.","family":"Connors","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen S.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothie Durosier","family":"Mertilus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.soncn.2026.152167_bib0001","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Genetic\/familial high-risk assessment: Breast, ovarian, pancreatic, and prostate. Version 1.2026. National Comprehensive Cancer Network; 2025\u20132026. Accessed September 18, 2025. Available at: https:\/\/www.nccn.org"},{"issue":"5","key":"10.1016\/j.soncn.2026.152167_bib0002","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.soncn.2026.152167_bib0003","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41436-018-0009-5","article-title":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","volume":"21","author":"Yurgelun","year":"2019","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.soncn.2026.152167_bib0004","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.soncn.2026.152167_bib0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.soncn.2026.152167_bib0006","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO-society of surgical oncology guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2026.152167_bib0007","series-title":"ONS Genomics and Precision Oncology Competencies for Nurses","year":"2023"},{"key":"10.1016\/j.soncn.2026.152167_bib0008","series-title":"Cancer Genetics for the Oncology Nurse","author":"Mahon","year":"2022"},{"issue":"1","key":"10.1016\/j.soncn.2026.152167_bib0009","article-title":"Oncology nurses\u2019 roles in implementing precision oncology and genomic testing","volume":"40","author":"Mahmoud","year":"2024","journal-title":"Semin Oncol Nurs"},{"issue":"11","key":"10.1016\/j.soncn.2026.152167_bib0010","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.11124\/JBIES-24-00009","article-title":"Nursing strategies to address health disparities in genomics-informed care: a scoping review","volume":"22","author":"Limoges","year":"2024","journal-title":"JBI Evid Synth"},{"issue":"5","key":"10.1016\/j.soncn.2026.152167_bib0011","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"23","key":"10.1016\/j.soncn.2026.152167_bib0012","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMsr1406261","article-title":"ClinGen\u2014the clinical genome resource","volume":"372","author":"Rehm","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2026.152167_bib0013","unstructured":"Premnath SM, Zubair M. Laboratory evaluation of tumor biomarkers. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK597378\/. [Updated 2023 Oct 28]."},{"issue":"10","key":"10.1016\/j.soncn.2026.152167_bib0014","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41576-021-00390-4","article-title":"Addressing health disparities in cancer with genomics","volume":"22","author":"Balogun","year":"2021","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.soncn.2026.152167_bib0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000338393","article-title":"Tumor markers in clinical practice: a review focusing on common solid cancers","volume":"22","author":"Duffy","year":"2013","journal-title":"Med Princ Pract"},{"issue":"12","key":"10.1016\/j.soncn.2026.152167_bib0016","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","article-title":"National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers","volume":"54","author":"Sturgeon","year":"2008","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.soncn.2026.152167_bib0017","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.molonc.2014.10.004","article-title":"Biomarker validation and testing","volume":"9","author":"Hayes","year":"2015","journal-title":"Mol Oncol"},{"issue":"6","key":"10.1016\/j.soncn.2026.152167_bib0018","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.3390\/biomedicines13061386","article-title":"Comparative study of elevated CA19-9 levels in non-gastrointestinal tumors patients: evaluation of different immunoassay methods and analysis of potential interfering factors","volume":"13","author":"Liu","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.soncn.2026.152167_bib0019","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.breast.2020.05.005","article-title":"Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance","volume":"52","author":"Hing","year":"2020","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.soncn.2026.152167_bib0020","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14737159.2017.1326820","article-title":"The role of biomarkers in the management of epithelial ovarian cancer","volume":"17","author":"Yang","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"10.1016\/j.soncn.2026.152167_bib0021","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.soncn.2026.152167_bib0022","doi-asserted-by":"crossref","first-page":"4","DOI":"10.14740\/wjon1425","article-title":"Carcinoembryonic antigen, carbohydrate antigen 19-9, cancer antigen 125, prostate-specific antigen and other cancer markers: a primer on commonly used cancer markers","volume":"14","author":"Desai","year":"2023","journal-title":"World J Oncol."},{"key":"10.1016\/j.soncn.2026.152167_bib0023","unstructured":"National Cancer Institute. (2022). Prostate-specific antigen (PSA) test. Accessed January 26, 2026. https:\/\/www.cancer.gov\/types\/prostate\/psa-fact-sheet."},{"issue":"10","key":"10.1016\/j.soncn.2026.152167_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjon.2024.100566","article-title":"When clinical advances outpace knowledge: the role of nurses in precision oncology","volume":"11","author":"D\u00edez de Los R\u00edos de la Serna","year":"2024","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"8","key":"10.1016\/j.soncn.2026.152167_bib0025","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soncn.2026.152167_bib0026","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"npj Precis. Onc."},{"issue":"12","key":"10.1016\/j.soncn.2026.152167_bib0027","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.amjmed.2024.08.014","article-title":"Circulating tumor DNA for solid tumor minimal\/molecular residual disease detection in cancer survivors","volume":"137","author":"Sorscher","year":"2024","journal-title":"Am J Med"},{"issue":"1130","key":"10.1016\/j.soncn.2026.152167_bib0028","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern","volume":"95","author":"Wilkinson","year":"2022","journal-title":"Br J Radiol"},{"issue":"10074","key":"10.1016\/j.soncn.2026.152167_bib0029","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"issue":"10087","key":"10.1016\/j.soncn.2026.152167_bib0030","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.soncn.2026.152167_bib0031","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41698-025-01016-2","article-title":"Mucin-1: a promising pan-cancer therapeutic target","volume":"9","author":"Grewal","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.soncn.2026.152167_bib0032","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13058-019-1235-8","article-title":"Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer","volume":"21","author":"Fernandez-Garcia","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"26","key":"10.1016\/j.soncn.2026.152167_bib0033","doi-asserted-by":"crossref","first-page":"43180","DOI":"10.18632\/oncotarget.17858","article-title":"Characterization of the release and biological significance of cell-free DNA from breast cancer cell lines","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.soncn.2026.152167_bib0034","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/cancers14020310","article-title":"Role of ctDNA in breast cancer","volume":"14","author":"Sant","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.soncn.2026.152167_bib0035","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soncn.2026.152167_bib0036","series-title":"Cancer Facts & Figures 2025","year":"2025"},{"issue":"6","key":"10.1016\/j.soncn.2026.152167_bib0037","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.soncn.2026.152167_bib0038","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/aogs.14224","article-title":"The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis","volume":"100","author":"Olsen","year":"2021","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"10.1016\/j.soncn.2026.152167_bib0039","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2010.02.005","article-title":"Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass","volume":"117","author":"Nolen","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.soncn.2026.152167_bib0040","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.soncn.2026.152167_bib0041","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12958-021-00860-8","article-title":"Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer","volume":"19","author":"Yang","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"issue":"1","key":"10.1016\/j.soncn.2026.152167_bib0042","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41525-022-00300-5","article-title":"Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer","volume":"7","author":"Vanderstichele","year":"2022","journal-title":"NPJ Genom Med"},{"issue":"4","key":"10.1016\/j.soncn.2026.152167_bib0043","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.soncn.2026.152167_bib0044","unstructured":"National Comprehensive Cancer Network. (2024). NCCN Guidelines for Patients: Pancreatic Cancer (2024th ed.). National Comprehensive Cancer Network. https:\/\/www.nccn.org\/."},{"key":"10.1016\/j.soncn.2026.152167_bib0045","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. (2024). Carbohydrate Antigen (CA) 19-9 pretreatment lab value. SEER staging resources. https:\/\/staging.seer.cancer.gov\/eod_public\/input\/3.3\/pancreas\/ca19_9_pretx_lab_value\/"},{"issue":"26","key":"10.1016\/j.soncn.2026.152167_bib0046","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.3748\/wjg.v27.i26.4045","article-title":"Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?","volume":"27","author":"O'Neill","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.soncn.2026.152167_bib0047","first-page":"11683","article-title":"Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis","volume":"8","author":"Zhang","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"10.1016\/j.soncn.2026.152167_bib0048","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12967-018-1677-2","article-title":"Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer","volume":"16","author":"Lapin","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.soncn.2026.152167_bib0049","unstructured":"National Cancer Institute. (2022). Prostate-specific antigen (PSA) test. https:\/\/www.cancer.gov\/types\/prostate\/psa-fact-sheet. Accessed August 1, 2025."},{"issue":"21","key":"10.1016\/j.soncn.2026.152167_bib0050","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122109","article-title":"Tumor fraction in cell-free DNA as a biomarker in prostate cancer","volume":"3","author":"Choudhury","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.soncn.2026.152167_bib0051","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.soncn.2026.152167_bib0052","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CU9.0000000000000145","article-title":"Prostate cancer screening: Continued controversies and novel biomarker advancements","volume":"16","author":"Tidd-Johnson","year":"2022","journal-title":"Curr Urol"},{"key":"10.1016\/j.soncn.2026.152167_bib0053","article-title":"Genetic alterations detected in cell-free DNA are associated with enzalutamide and abiraterone resistance in castration-resistant prostate cancer","volume":"3","author":"Torquato","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.soncn.2026.152167_bib0054","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","article-title":"Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant","volume":"28","author":"Tolaney","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.soncn.2026.152167_bib0055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.soncn.2026.152167_bib0056","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pan.2020.12.017","article-title":"Molecular profiling of ctDNA in pancreatic cancer: opportunities and challenges for clinical application","volume":"21","author":"Sivapalan","year":"2021","journal-title":"Pancreatology"},{"issue":"1","key":"10.1016\/j.soncn.2026.152167_bib0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clgc.2019.09.015","article-title":"Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer","volume":"18","author":"Zhang","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"22","key":"10.1016\/j.soncn.2026.152167_bib0058","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.soncn.2026.152167_bib0059","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.763790","article-title":"Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives","volume":"11","author":"Peng","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.soncn.2026.152167_bib0060","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12672-025-01940-6","article-title":"Beyond traditional biopsies: the emerging role of ctDNA and MRD on breast cancer diagnosis and treatment","volume":"16","author":"Sabit","year":"2025","journal-title":"Discov Oncol"},{"issue":"10","key":"10.1016\/j.soncn.2026.152167_bib0061","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","article-title":"Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance","volume":"10","author":"Pettitt","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.soncn.2026.152167_bib0062","series-title":"Genetics and Genomics in Oncology Nursing Practice","year":"2021"},{"key":"10.1016\/j.soncn.2026.152167_bib0063","series-title":"Cancer Control: Knowledge into Action","year":"2017"},{"issue":"16","key":"10.1016\/j.soncn.2026.152167_bib0064","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.soncn.2026.152167_bib0065","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.soncn.2026.152167_bib0066","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/apjon.apjon_1_18","article-title":"Oncology nurses: innovating precision care in a changing treatment environment","volume":"5","author":"Nevidjon","year":"2018","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"34","key":"10.1016\/j.soncn.2026.152167_bib0067","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2017.73.6314","article-title":"National estimates of genetic testing in women with a history of breast or ovarian cancer","volume":"35","author":"Childers","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.soncn.2026.152167_bib0068","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11606-016-3943-4","article-title":"Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: a systematic review and research agenda","volume":"32","author":"Hamilton","year":"2017","journal-title":"J Gen Intern Med"},{"issue":"4","key":"10.1016\/j.soncn.2026.152167_bib0069","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ajhg.2018.02.009","article-title":"Outcomes of counseling after education about carrier results: a randomized controlled trial","volume":"102","author":"Lewis","year":"2018","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.soncn.2026.152167_bib0070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/jnu.12380","article-title":"The global landscape of nursing and genomics","volume":"50","author":"Calzone","year":"2018","journal-title":"J Nurs Scholarsh"},{"issue":"2","key":"10.1016\/j.soncn.2026.152167_bib0071","first-page":"394","article-title":"Barriers and facilitators influencing nurses in genetic services provision: a systematic review","volume":"66","author":"Latha","year":"2025","journal-title":"Niger Med J"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208126000471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208126000471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T22:46:01Z","timestamp":1774997161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208126000471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0749208126000471"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2026.152167","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From Serum Markers to Liquid Biopsy: Precision Monitoring in Breast, Ovarian, Pancreatic, and Prostate Cancers","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2026.152167","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152167"}}